Alexandria Real Estate Equities-backed exosome therapeutics developer Codiak BioSciences is eyeing up to $86.3m in a forthcoming IPO.
Codiak BioSciences, a US-based exosome therapeutics developer backed by life science real estate investment trust Alexandria Real Estate Equities, has filed to raise up to $86.3m in an initial public offering.
Founded in 2015, Codiak is developing exosome therapeutics to treat a range of conditions, including cancer, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders and rare diseases.
The company’s therapeutics are created by engineering exosomes, extracellular vesicles that are produced by nearly all cells in the human body…
